BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

...c-Met receptor tyrosine kinase EGFR (ErbB1; HER1) – Epidermal growth factor receptorGPR84 – G protein-coupled receptor...
BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

...Investment and Widwin Investment.   TARGETSHIF-PH (EGLN) – Hypoxia-inducible factor prolyl hydroxylasePTGDR1 (DP1) – Prostaglandin D2 receptor...
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...KGFR; CD332) – Fibroblast growth factor (FGF) receptor...
...FGFR3; CD333) – Fibroblast growth factor (FGF) receptor...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

...Tigermed Consulting Co. Ltd (SZSE:300347) and Lyfe Capital.TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor...
BioCentury | Dec 2, 2020
Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

...Quang, Staff Writer DISEASE CATEGORY: Infectious diseaseINDICATION: SepsisInhibiting the scaffold protein SQSTM1 or its extracellular receptor...
...peptide modulator of SQSTM1, in Phase III testing for mucositis.TARGET/MARKER/PATHWAY: Sequestosome 1 (SQSTM1; p62); insulin receptor...
...Dallas, Texasemail: rui.kang@utsouthwestern.edu Claire Quang Third Military Medical University University of Texas Southwestern Medical Center Sequestosome 1 (SQSTM1) (p62) Insulin receptor...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

...Type II diabetes and has the drug in Phase II testing for heart failure.TARGET/MARKER/PATHWAY: Glucagon-like peptide-1 receptor...
...Qi N. Cui, same affiliation as aboveemail: qi.cui@pennmedicine.upenn.edu Claire Quang NLY01 (pegylated exenatide) University of Pennsylvania Neuraly Inc. Glucagon-like peptide-1 receptor...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Inhibiting vesicular trafficking protein SURF4 to treat atherosclerosis

...By Claire Quang, Staff Writer DISEASE CATEGORY: CardiovascularINDICATION: AtherosclerosisTargeting the ER cargo receptor SURF4 could treat...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...granted Biohaven Pharmaceutical Holding Co. Ltd. (NASDAQ:BHVN) rights to a portfolio of small molecule CGRP receptor...
...and is eligible for $370 million in milestones, plus royalties. Biohaven markets one oral CGRP receptor...
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...glutamate receptor subtype 3 (mGluR3) (GRM3)Metabotropic glutamate receptor...
...glutamate receptor subtype 2 (mGluR2) (GRM2) Metabotropic glutamate receptor...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

...using an antibody to target a tumor antigen, this is using a soluble T cell receptor...
Items per page:
1 - 10 of 35362